Arcturus Therapeutics (ARCT) Competitors $17.01 -0.29 (-1.68%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$17.02 +0.01 (+0.06%) As of 08/29/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. ADPT, SRPT, ANIP, ARQT, VCEL, DYN, APGE, TWST, BEAM, and CDTXShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), ANI Pharmaceuticals (ANIP), Arcutis Biotherapeutics (ARQT), Vericel (VCEL), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Beam Therapeutics (BEAM), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Its Competitors Adaptive Biotechnologies Sarepta Therapeutics ANI Pharmaceuticals Arcutis Biotherapeutics Vericel Dyne Therapeutics Apogee Therapeutics Twist Bioscience Beam Therapeutics Cidara Therapeutics Arcturus Therapeutics (NASDAQ:ARCT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Do analysts prefer ARCT or ADPT? Arcturus Therapeutics presently has a consensus price target of $50.57, indicating a potential upside of 197.30%. Adaptive Biotechnologies has a consensus price target of $12.38, indicating a potential downside of 6.11%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Does the media favor ARCT or ADPT? In the previous week, Adaptive Biotechnologies had 8 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 4 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.48 beat Adaptive Biotechnologies' score of 1.30 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ARCT or ADPT? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 15.3% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, ARCT or ADPT? Arcturus Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Is ARCT or ADPT more profitable? Arcturus Therapeutics has a net margin of -49.26% compared to Adaptive Biotechnologies' net margin of -59.07%. Arcturus Therapeutics' return on equity of -24.87% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-49.26% -24.87% -17.75% Adaptive Biotechnologies -59.07%-60.93%-23.03% Which has stronger earnings & valuation, ARCT or ADPT? Arcturus Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M3.03-$80.94M-$2.23-7.63Adaptive Biotechnologies$178.96M11.21-$159.49M-$0.82-16.07 SummaryArcturus Therapeutics beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$461.90M$3.08B$5.71B$9.76BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-7.6320.7883.1026.57Price / Sales3.03393.33544.91112.35Price / CashN/A43.5325.6628.92Price / Book1.919.7811.766.08Net Income-$80.94M-$54.01M$3.27B$265.84M7 Day Performance-3.95%0.10%1.13%0.36%1 Month Performance38.29%8.52%8.30%5.58%1 Year Performance-19.38%7.03%62.26%19.67% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.6914 of 5 stars$17.01-1.7%$50.57+197.3%-19.4%$461.90M$152.31M-7.63180ADPTAdaptive Biotechnologies2.5069 of 5 stars$12.67-2.5%$12.38-2.3%+180.4%$1.98B$178.96M-15.45790News CoveragePositive NewsSRPTSarepta Therapeutics4.4899 of 5 stars$18.06-10.7%$43.50+140.9%-86.6%$1.98B$1.90B-20.761,372ANIPANI Pharmaceuticals3.7237 of 5 stars$90.32-0.8%$84.75-6.2%+46.7%$1.97B$614.38M-117.30600Positive NewsARQTArcutis Biotherapeutics2.4581 of 5 stars$15.69-1.8%$19.80+26.2%+42.6%$1.92B$196.54M-20.92150Positive NewsVCELVericel2.3079 of 5 stars$35.79-3.3%$60.33+68.6%-29.6%$1.87B$237.22M298.27300Positive NewsDYNDyne Therapeutics3.6599 of 5 stars$13.00+3.3%$34.07+162.1%-70.7%$1.79BN/A-3.37100News CoveragePositive NewsAPGEApogee Therapeutics3.7587 of 5 stars$36.94-3.5%$99.00+168.0%-28.9%$1.76BN/A-8.9491News CoveragePositive NewsTWSTTwist Bioscience3.8893 of 5 stars$27.39-4.2%$49.40+80.4%-37.6%$1.73B$312.97M-18.89990Positive NewsBEAMBeam Therapeutics2.1932 of 5 stars$16.44-1.2%$48.45+194.7%-38.7%$1.68B$60.27M-3.65510Positive NewsCDTXCidara Therapeutics3.4887 of 5 stars$64.13-3.4%$64.14+0.0%+450.0%$1.68B$1.27M-5.7690Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Sarepta Therapeutics Alternatives ANI Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Vericel Alternatives Dyne Therapeutics Alternatives Apogee Therapeutics Alternatives Twist Bioscience Alternatives Beam Therapeutics Alternatives Cidara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts